L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells
详细信息 查看全文
- 作者：Soo-A. Junga ; b ; 1 ; Dae-Hee Leea ; b ; 1 ; Jai-Hee Moona ; b ; Seung-Woo Honga ; b ; Jae-Sik Shina ; b ; Ih Yeon Hwanga ; b ; Yu Jin Shina ; b ; Jeong Hee Kima ; b ; Eun-Yeung Gonga ; b ; Seung-Mi Kima ; b ; Eun Young Leea ; b ; Seul Leea ; b ; Jeong Eun Kima ; b ; Kyu-pyo Kima ; b ; Yong Sang Honga ; b ; Jung Shin Leea ; b ; Dong-Hoon Jina ; b ; c ; inno183@amc.seoul.kr" class="auth_mail" title="E-mail the corresponding author ; TaeWon Kima ; b ; twkimmd@amc.seoul.kr" class="auth_mail" title="E-mail the corresponding author ; Wang Jae Leed
- 关键词：SVCT-2 ; sodium-dependent vitamin C transporter 2 ; CRC ; colorectal cancer ; EGFR ; epidermal growth factor receptor
- 刊名：Free Radical Biology and Medicine
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：95
- 期：Complete
- 页码：200-208
- 全文大小：5284 K
文摘
- •
- •
Combinational treatment with cetuximab and
- •
SVCT-2 is a potent marker for the treatment of